Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   Aminoglycoside/tetracycline Resistance (ATR)
AR Bank # 0565 Staphylococcus aureus
Study ID: ATR-25

Biosample Accession #: SAMN11953997

MLST: 239(Pasteur)

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Panel:  Aminoglycoside/tetracycline Resistance (ATR)  |  Aminoglycoside/tetracycline Resistance - Gram positive set (ATR-GP) (Custom)

MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Cefoxitin 2>16R
Ceftaroline 1S
Clindamycin >16R
Colistin 4>16---
Daptomycin 1S
Doxycycline 16R
Eravacycline 30.12NS
Erythromycin >8R
Gentamicin >64R
Levofloxacin 16R
Linezolid <=1.0S
Mupirocin <=4---
Omadacycline 30.25S
Oxacillin >16R
Penicillin >2R
Rifampin <=0.5S
Streptomycin >64---
Tetracycline >64R
Trimethoprim/sulfamethoxazole 1>8R
Vancomycin 2S
SDD (Susceptible Dose Dependent)
S – I –R Interpretation (INT) derived from CLSI 2024 M100 S34

1 Reflects MIC of first component
2 Cefoxitin is tested as a surrogate for mecA-mediated oxacillin resistance
3 Based on FDA break points
4 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
Aminoglycoside aac(6')-Ie, ant(9)-Ia, aph(3')-IIIa, aph-STPH
Beta-lactam blaI, mecA, Z
Efflux pumps/Other LMRS, MEPA
Fosfomycin fosB
Macrolide-Lincosamide-Streptogramin erm(A)
Phenicols/Bicyclomycins DHA-1
Quinolone norA
Streptothricin sat4
Tetracyclines tet(38), tet(K), tet(M)
Trimethoprim dfrG
AR gene prediction was performed using ARG-ANNOT and ResFinder databases accessed on 20180608. AR drug classes are assigned according to these databases. This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of used database or other antimicrobial resistance gene databases. For resistance determinant detection, 99-100% sequence identity and 100% sequence coverage from GAMMA and SRST2 was used. GAMMA uses amino acid sequence to assign gene alleles from assemblies; SRST2 uses nucleotide sequence to assign gene alleles from sequencing reads. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired. *MLST Type (and scheme), as determined by Torsten Seemann's MLST program. For Enterobacteriaceae, the Pasteur MLST schemes are used except for E. coli for which both the Pasteur and Achtman schemes are reported. SUB=novel MLST identified and "submitted". **Presence of Efflux Pump may not be associated with resistance.
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

Temperature: 35°C
Atmosphere: Aerobic


Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.

Storage Temperature & Biosafety

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
01/18/23MIC was updated with a new value for Eravacycline: from '0.25' to '0.12'
11/16/22Gene was removed from 'from '---' to ' R1''
11/16/22Gene was removed from 'from '---' to ' mecR1''
11/16/22Gene was removed from 'from '---' to ' mecI''
11/07/22MLST was updated
09/26/22Gene was added
09/26/22Gene was removed
09/13/22Gene was added
09/13/22Category was added
09/13/22Gene was added
09/13/22Category was added
09/13/22Gene was removed
09/13/22Gene was added
09/13/22Gene was removed
Top of Page